Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Daniel Hog

Philip Lienau

Ulrich Lücking

Nicolas Werbeck

Clara Christ

Ulrike Sack

Franziska Siegel

Gerhard Siemeister

Arne Scholz

Jens Geisler

Kirstin Petersen

Christian Stegmann

Dorothee Andres

Gang Chen

Simon Anthony Herbert

Ping Gao

Jiajun Xi

Kunzeng Zheng

The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

PTEFB inhibiting macrocyclic compounds

The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). 

PTEFb inhibiting macrocyclic compounds

The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). 

Macrocyclic sulfondiimine compounds

The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

Modified macrocyclic compounds

Growing community of inventors

Düsseldorf, Germany

Daniel Hog